Trial · NCT02258542
Outcomes42
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 42
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Full analysis set, excluding MELTEMI patients. For each lab tests, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Full analysis set, adolescents only (studies SIROCCO/CALIMA only, study ZONDA does not enroll adolescents). For each lab tests, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Full analysis set, excluding MELTEMI patients. For each lab tests, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Full analysis set, adolescents only (studies SIROCCO/CALIMA only, study ZONDA does not enroll adolescents). For each lab tests, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Full analysis set, excluding MELTEMI patients. For each lab tests, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Full analysis set, adolescents only (studies SIROCCO/CALIMA only, study ZONDA does not enroll adolescents). For each lab tests, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Full analysis set, excluding MELTEMI patients. For each lab tests, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Full analysis set, adolescents only (studies SIROCCO/CALIMA only, study ZONDA does not enroll adolescents). For each lab tests, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Full analysis set, excluding MELTEMI patients. For each lab tests, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Full analysis set, adolescents only(studies SIROCCO/CALIMA only, study ZONDA does not enroll adolescents). For each lab tests, number of patients is the number of patients with available change from baseline value. | 10^9 cells/L | MEAN |
| PRIMARY | Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Full analysis set, excluding MELTEMI patients. For each lab tests, number of patients is the number of patients with available change from baseline value. | ukat/L | MEAN |
| PRIMARY | Change From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Full analysis set, adolescents only (studies SIROCCO/CALIMA only, study ZONDA does not enroll adolescents). For each lab tests, number of patients is the number of patients with available change from baseline value. | ukat/L | MEAN |
| PRIMARY | Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Full analysis set, excluding MELTEMI patients. For each lab tests, number of patients is the number of patients with available change from baseline value. | ukat/L | MEAN |
| PRIMARY | Change From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Full analysis set, adolescents only (studies SIROCCO/CALIMA only, study ZONDA does not enroll adolescents). For each lab tests, number of patients is the number of patients with available change from baseline value. | ukat/L | MEAN |
| PRIMARY | Change From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Full analysis set, excluding MELTEMI patients. For each lab tests, number of patients is the number of patients with available change from baseline value. | umol/L | MEAN |
| PRIMARY | Change From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Full analysis set, adolescents only (studies SIROCCO/CALIMA only, study ZONDA does not enroll adolescents). For each lab tests, number of patients is the number of patients with available change from baseline value. | umol/L | MEAN |
| SECONDARY | Number of Overall Patients With Asthma Exacerbations During Study Period | From week 0 to week 56 in study treatment period and through the follow up period (16 weeks from day of last dose) | Full analysis set, excluding MELTEMI patients. Summarized by subsets of patients enrolled from SIROCCO/CALIMA with baseline eosinophils count \>=300/uL or \<300/uL; all patients enrolled from ZONDA; separated by predecessor treatment groups. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Overall Patients With Asthma Exacerbations During Study Period, Adolescents Only (SIROCCO/CALIMA) | From week 0 to week 108 in study treatment period and through the follow up period (16 weeks from day of last dose) | Full analysis set, adolescents only (studies SIROCCO/CALIMA only, study ZONDA does not enroll adolescents). Summarized by subsets of patients enrolled from SIROCCO/CALIMA with baseline eosinophils count \>=300/uL or \<300/uL; separated by predecessor treatment groups. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in Pre-bronchodilator FEV1 (L) | Week 56 | Full analysis set, excluding MELTEMI patients. For patients enrolled from SIROCCO/CALIMA, summarized by baseline eosinophils count\>=300/uL, and \<300/uL; all patients enrolled from ZONDA; separated by predecessor treatment groups. | L | MEAN |
| SECONDARY | Change From Baseline in Pre-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA) | Week 108 | Full analysis set, adolescents only (studies SIROCCO/CALIMA only, study ZONDA does not enroll adolescents). Summarized by subsets of patients enrolled from SIROCCO/CALIMA with baseline eosinophils count \>=300/uL or \<300/uL; separated by predecessor treatment groups. | L | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02258542/outcomes